Skip to main content

Table 2 Clinical characteristics of patients in unweighted, greedy-matching, and stabilized inverse probability of treatment–weighed samples

From: Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab

Characteristics (mean ± SD or n(%))

Total (n = 410)

Unweighted

Greedy matching

Stabilized IPTW

Tofacitinib

Adalimumab

SMD

Tofacitinib

Adalimumab

SMD

Tofacitinib

Adalimumab

SMD

(n = 281)

(n = 129)

(n = 139)

(n = 92)

(n = 226)

(n = 99)

CCI score

 0

339 (82.68)

229 (81.5)

110 (85.27)

0.108

119 (85.61)

79 (85.87)

0.062

187 (82.76)

80 (83.04)

0.068

 1

58 (14.15)

42 (14.95)

16 (12.4)

18 (12.95)

11 (11.96)

33 (14.52)

15 (15.22)

 2 ≤ 

13 (3.17)

10 (3.56)

3 (2.33)

2 (1.44)

2 (2.17)

6 (2.72)

2 (1.74)

Disease duration (months)

67.38 ± 70.13

71.32 ± 70.52

58.87 ± 68.79

0.179

59.15 ± 62.59

61.05 ± 71.87

0.028

70.72 ± 70.00

67.92 ± 80.92

0.037

Duration of current treatment (months)

11.33 ± 5.11

11.23 ± 4.93

11.55 ± 5.49

0.061

11.07 ± 4.97

11.25 ± 5.34

0.035

11.26 ± 4.99

11.19 ± 5.25

0.014

Concomitant use of MTX

 Yes

331 (81.73)

211 (75.63)

120 (95.24)

0.579

128 (92.09)

87 (94.57)

0.099

180 (79.94)

81 (83.27)

0.086

 No

74 (18.27)

68 (24.37)

6 (4.76)

11 (7.91)

5 (5.44)

45 (20.06)

16 (16.73)

MTX dose (1000 mg)

2.07 ± 2.81

1.96 ± 2.82

2.31 ± 2.78

0.124

2.26 ± 3.09

2.35 ± 2.66

0.030

2.09 ± 2.99

2.37 ± 2.97

0.095

Concomitant use of NSAIDs

 Yes

289 (70.49)

200 (71.17)

89 (68.99)

0.048

104 (74.82)

67 (72.83)

0.045

163 (72.17)

70 (72.05)

0.003

 No

121 (29.51)

81 (28.83)

40 (31.01)

35 (25.18)

25 (27.17)

63 (27.84)

27 (27.95)

Concomitant use of steroid

 Yes

289 (70.49)

202 (71.89)

87 (67.44)

0.097

99 (71.22)

61 (66.3)

0.106

156 (69.34)

67 (69.12)

0.005

 No

121 (29.51)

79 (28.11)

42 (32.56)

40 (28.78)

31 (33.7)

69 (30.66)

30 (30.88)

DAS28-CRP

2.67 ± 1.17

2.65 ± 1.16

2.71 ± 1.19

0.052

2.67 ± 1.16

2.768 ± 1.212

0.082

2.705 ± 1.233

2.826 ± 1.348

0.094

DAS28-ESR

3.33 ± 1.30

3.35 ± 1.26

3.30 ± 1.39

0.032

3.31 ± 1.17

3.320 ± 1.396

0.010

3.380 ± 1.297

3.434 ± 1.551

0.038

DAS28 components

 ESR (mm/h)

24.63 ± 20.06

25.07 ± 18.93

23.69 ± 22.37

0.066

22.66 ± 15.25

23.17 ± 20.81

0.028

25.17 ± 18.36

27.48 ± 25.81

0.103

 CRP

4.00 ± 9.27

3.97 ± 9.77

4.07 ± 8.12

0.012

4.31 ± 12.72

4.81 ± 9.20

0.045

4.76 ± 13.58

6.22 ± 10.09

0.123

 Tender joint count

2.74 ± 3.95

2.58 ± 3.84

3.09 ± 4.18

0.126

2.73 ± 4.00

3.11 ± 4.13

0.092

2.88 ± 4.36

3.12 ± 4.72

0.051

 Swollen joint count

1.909 ± 3.832

1.793 ± 3.721

2.164 ± 4.068

0.095

1.892 ± 3.812

2.21 ± 4.02

0.080

2.13 ± 4.33

2.41 ± 4.68

0.061

 GH VAS

28.96 ± 20.62

29.93 ± 21.15

26.89 ± 19.37

0.150

29.07 ± 20.88

27.32 ± 19.53

0.086

29.00 ± 21.11

29.68 ± 20.58

0.033

  1. IPTW inverse probability of treatment weighting, SD standard deviation, n number, SMD standardized mean differences, CCI score Charlson Comorbidity Index score, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs, DAS Disease Activity Score, CRP C-reactive protein level, ESR erythrocyte sedimentation rate, GH general health, VAS visual analog scale